High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019

Charles Vesteghem,1– 3 Rasmus Froberg Brøndum,1– 3 Ursula G Falkmer,1,3,4 Anton Pottegård,5 Laurids Østergaard Poulsen,1,3,4 Martin Bøgsted1– 3 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 2Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; 3Clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vesteghem C, Brøndum RF, Falkmer UG, Pottegård A, Poulsen LØ, Bøgsted M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	antineoplastic agents registries danish national patient registry epidemiology sensitivity and specificity validity Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/a780ffad1b0b43d2887e12278710f718
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a780ffad1b0b43d2887e12278710f718
record_format	dspace
spelling	oai:doaj.org-article:a780ffad1b0b43d2887e12278710f7182021-11-23T18:43:02ZHigh Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 20191179-1349https://doaj.org/article/a780ffad1b0b43d2887e12278710f7182021-11-01T00:00:00Zhttps://www.dovepress.com/high-validity-of-the-danish-national-patient-registry-for-systemic-ant-peer-reviewed-fulltext-article-CLEPhttps://doaj.org/toc/1179-1349Charles Vesteghem,1– 3 Rasmus Froberg Brøndum,1– 3 Ursula G Falkmer,1,3,4 Anton Pottegård,5 Laurids Østergaard Poulsen,1,3,4 Martin Bøgsted1– 3 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 2Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; 3Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark; 4Department of Oncology, Aalborg University Hospital, Aalborg, Denmark; 5Department of Public Health, University of Southern Denmark, Odense, DenmarkCorrespondence: Charles VesteghemDepartment of Clinical Medicine, Aalborg University, Søndre Skovvej 15, Aalborg, 9000, DenmarkTel +45 97 66 38 72Fax +45 97 66 63 23Email charles.vesteghem@rn.dkBackground: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time.Patients and Methods: We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV.Results: There was an overall high concordance between the two datasets with a sensitivity and a PPV > 92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81– 89%). The validity was stable over the study period, with a slight drop during 2016– 2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction.Conclusion: The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer.Keywords: antineoplastic agents, registries, Danish National Patient Registry, epidemiology, sensitivity and specificity, validityVesteghem CBrøndum RFFalkmer UGPottegård APoulsen LØBøgsted MDove Medical Pressarticleantineoplastic agentsregistriesdanish national patient registryepidemiologysensitivity and specificityvalidityInfectious and parasitic diseasesRC109-216ENClinical Epidemiology, Vol Volume 13, Pp 1085-1094 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antineoplastic agents registries danish national patient registry epidemiology sensitivity and specificity validity Infectious and parasitic diseases RC109-216
spellingShingle	antineoplastic agents registries danish national patient registry epidemiology sensitivity and specificity validity Infectious and parasitic diseases RC109-216 Vesteghem C Brøndum RF Falkmer UG Pottegård A Poulsen LØ Bøgsted M High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
description	Charles Vesteghem,1– 3 Rasmus Froberg Brøndum,1– 3 Ursula G Falkmer,1,3,4 Anton Pottegård,5 Laurids Østergaard Poulsen,1,3,4 Martin Bøgsted1– 3 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 2Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; 3Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark; 4Department of Oncology, Aalborg University Hospital, Aalborg, Denmark; 5Department of Public Health, University of Southern Denmark, Odense, DenmarkCorrespondence: Charles VesteghemDepartment of Clinical Medicine, Aalborg University, Søndre Skovvej 15, Aalborg, 9000, DenmarkTel +45 97 66 38 72Fax +45 97 66 63 23Email charles.vesteghem@rn.dkBackground: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time.Patients and Methods: We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV.Results: There was an overall high concordance between the two datasets with a sensitivity and a PPV > 92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81– 89%). The validity was stable over the study period, with a slight drop during 2016– 2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction.Conclusion: The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer.Keywords: antineoplastic agents, registries, Danish National Patient Registry, epidemiology, sensitivity and specificity, validity
format	article
author	Vesteghem C Brøndum RF Falkmer UG Pottegård A Poulsen LØ Bøgsted M
author_facet	Vesteghem C Brøndum RF Falkmer UG Pottegård A Poulsen LØ Bøgsted M
author_sort	Vesteghem C
title	High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_short	High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_full	High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_fullStr	High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_full_unstemmed	High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
title_sort	high validity of the danish national patient registry for systemic anticancer treatment registration from 2009 to 2019
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/a780ffad1b0b43d2887e12278710f718
work_keys_str_mv	AT vesteghemc highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT brøndumrf highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT falkmerug highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT pottegarda highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT poulsenlø highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT bøgstedm highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019
_version_	1718416171681710080

High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019

Ejemplares similares